Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study.
chronic kidney disease
comorbidity
hepatic steatosis
hypertension
hyperuricemia
non-alcoholic fatty liver disease
obesity
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
28 May 2020
28 May 2020
Historique:
received:
01
05
2020
revised:
22
05
2020
accepted:
25
05
2020
entrez:
3
6
2020
pubmed:
3
6
2020
medline:
3
6
2020
Statut:
epublish
Résumé
It is unclear whether the link between non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) is mediated by common risk factors. We aimed to elucidate the association between NAFLD and CKD using propensity score (PS)-matched analysis. We assessed 3725 Japanese individuals, excluding those with hepatitis B or C infection and men and women who consumed >30 and >20 g/day of alcohol, respectively. Of these, we enrolled 1097 Japanese subjects with NAFLD diagnosed by ultrasonography and 1097 PS-matched subjects without NAFLD. The prevalence of CKD was higher in subjects with NAFLD than in those without NAFLD before PS matching, but there was no significant difference between these groups in terms of CKD prevalence after PS matching. There was no difference in the prevalence of CKD between those with and without NAFLD in the subgroup analyses. Logistic regression analysis demonstrated that obesity, hypertension, and hyperuricemia were independent predictors of CKD, but NAFLD was not independently associated with CKD. In subjects with NAFLD, obesity, hypertension, and hyperuricemia were independent predictors of CKD. Thus, the link between NAFLD and CKD may be mediated by common risk factors. We recommend screening for CKD when patients with NAFLD have the aforementioned comorbidities.
Identifiants
pubmed: 32481684
pii: jcm9061635
doi: 10.3390/jcm9061635
pmc: PMC7356359
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Liver Int. 2012 Jul;32(6):911-8
pubmed: 22672642
Hepatol Int. 2016 Mar;10(2):340-6
pubmed: 26676626
Am J Med. 2010 Sep;123(9):836-846.e2
pubmed: 20800153
Clin Chim Acta. 2017 Oct;473:39-44
pubmed: 28811239
PLoS One. 2014 Feb 10;9(2):e88569
pubmed: 24520400
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Nutrients. 2017 Apr 14;9(4):
pubmed: 28420094
Sci Rep. 2018 Mar 16;8(1):4718
pubmed: 29549269
BMC Nephrol. 2020 Apr 3;21(1):115
pubmed: 32245423
J Formos Med Assoc. 2020 Jan;119(1 Pt 3):496-503
pubmed: 31353118
Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686-90
pubmed: 24042449
J Evid Based Med. 2019 Nov;12(4):235-242
pubmed: 31482688
J Hepatol. 2011 May;54(5):1020-9
pubmed: 21145850
Lancet. 2008 Jun 28;371(9631):2173-82
pubmed: 18586172
Circulation. 2003 Oct 28;108(17):2154-69
pubmed: 14581387
JAMA. 2007 Nov 7;298(17):2038-47
pubmed: 17986697
JAMA. 2004 Feb 18;291(7):844-50
pubmed: 14970063
Am J Kidney Dis. 2018 Mar;71(3):362-370
pubmed: 29132945
PLoS One. 2017 Jul 24;12(7):e0180951
pubmed: 28738057
J Am Coll Cardiol. 2019 Mar 5;73(8):948-963
pubmed: 30819364
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Ci Ji Yi Xue Za Zhi. 2019 Apr 23;32(1):65-69
pubmed: 32110523
J Intern Med. 2019 Dec;286(6):711-722
pubmed: 31359543
Biomed Rep. 2016 Aug;5(2):188-192
pubmed: 27446539
J Clin Lab Anal. 2019 Feb;33(2):e22657
pubmed: 30239032
Lancet. 2010 Apr 10;375(9722):1296-309
pubmed: 20382326
J Clin Med. 2020 Apr 09;9(4):
pubmed: 32283679
Clin Exp Nephrol. 2009 Dec;13(6):621-30
pubmed: 19513802
J Hepatol. 2017 May;66(5):1022-1030
pubmed: 28039099
J Hepatol. 2016 Aug;65(2):425-43
pubmed: 27091791
Intern Med. 2011;50(10):1081-7
pubmed: 21576832
J Hepatol. 2017 Dec;67(6):1274-1280
pubmed: 28870674
BMJ Open. 2017 Dec 27;7(12):e018483
pubmed: 29284721
Sci Rep. 2019 Apr 30;9(1):6681
pubmed: 31040373
Am J Nephrol. 2012;36(5):466-71
pubmed: 23128368
Diabetes Care. 2000 Jan;23(1):51-6
pubmed: 10857968
Clin Chim Acta. 2018 Sep;484:150-163
pubmed: 29803897